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As targeted personalized therapy becomes more widely used in human medicine, clients
will expect the veterinary clinician to be able to implement an evidence-based strategy
regarding both the prescribing of medicines and also recognition of the potential for
adverse drug reactions (ADR) for their pet, at breed and individual level. This review aims
to provide an overview of current developments and challenges in pharmacogenetics
in medicine for a veterinary audience and to map these to developments in veterinary
pharmacogenetics. Pharmacogenetics has been in development over the past 100
years but has been revolutionized following the publication of the human, and then
veterinary species genomes. Genetic biomarkers called pharmacogenes have been
identified as specific genetic loci on chromosomes which are associated with either
positive or adverse drug responses. Pharmacogene variationmay be classified according
to the associated drug response, such as a change in (1) the pharmacokinetics; (2) the
pharmacodynamics; (3) genes in the downstream pathway of the drug or (4) the effect
of “off-target” genes resulting in a response that is unrelated to the intended target.
There are many barriers to translation of pharmacogenetic information to the clinic,
however, in human medicine, international initiatives are promising real change in the
delivery of personalized medicine by 2025. We argue that for effective translation into
the veterinary clinic, clinicians, international experts, and stakeholders must collaborate
to ensure quality assurance and genetic test validation so that animals may also benefit
from this genomics revolution.
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INTRODUCTION
Pharmacogenetics has been defined in human medicine as the “variability due to hereditary” (1)
and as such, the concept pre-dates the discoveries of the Human Genome project. The term
“pharmacogenomics” initially was used to describe the development of new drugs based on new
understanding provided by genomic research, and although the terms “pharmacogenetics” and
“pharmacogenomics” are often used interchangeably (1), “pharmacogenomics” is considered to
focus on the “expressed genome” and techniques to study drug responses include proteomics,
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metabolomics, and gene expression (2). To encompass both
concepts, the abbreviation PGx has come into use, defined as “the
individualization of drug therapy through medication selection
or dose adjustment based upon direct (e.g., genotyping) or
indirect (e.g., phenotyping) assessment of an individual’s genetic
constitution for drug response” Swen et al. (3). A closely linked
concept is “personalized medicine” which has been redefined for
the modern era as “the use of combined knowledge (genetic
or otherwise) about a person to predict disease susceptibility,
disease prognosis, or treatment response and thereby improve
that person’s health (4).”
Since drugs have first been used inman, it has been recognized
that certain individuals respond differently to certain drugs than
others do. These differing responses may now be attributed to the
individual’s genotype. With increased understanding of genetic
differences in human populations, and between individuals,
the concept of “precision medicine” is gaining currency. In
Europe, the recently established European Commission-funded
Ubiquitous-Pharmacogenomics Consortium (U-PGx), aims to
make personalized medicine prescribing accessible to every
European citizen (5).
Within the veterinary sphere, except for very specific broadly
understood geneticmutations such asMDR-1/ABCD-1mutation
in canine herding breeds, the direct application of PGx to
clinical prescribing has been limited to date. However, as targeted
medicine becomes more widely used in human medicine, clients
may expect that the veterinary clinician should also be able
to implement an evidence-based strategy regarding both the
prescribing of medicines and also recognition of the potential
for adverse drug reactions (ADR) for their animal, at breed and
individual level.
This review aims to provide an overview of the current
developments and challenges in PGx in medicine for a veterinary
audience, to map to and expand on these with respect to
current PGx knowledge and potential developments in veterinary
pharmacotherapeutics.
GENETIC VARIATION IN MAN AND
DOMESTIC SPECIES
Responses to drugs and adverse reaction to drug treatment, in
both humans and animals are influenced by a number of factors
such as age, gender, environment, and by an individual’s genetic
make-up which may be influenced by ethnicity or in the case of
animals, breed. Genetic variants arise within a species as a result
of DNA base pair substitutions resulting in single nucleotide
polymorphisms (SNPs) or as a result of either an insertion or
deletion in a sequence (indels). SNPs are relatively common
and are considered to occur in approximately 1 in 1,000 base
pairs in the human genome (6). SNPs and indels, if located in
the coding region of genes, may have significant effects on key
protein production within cells (6).
A change in genetic variant frequency at population level, or
“genetic drift,” occurs naturally as a result of “bottleneck” events,
when populations fall below a certain level and subgroup of a
species are cut off from each other, with the net result that certain
genetic variants alleles could become “lost”; conversely, certain
variants could become predominant. Variation may also occur as
a result of the selection pressures which different populations are
subjected to, for example, in humans, the heritable trait glucose-
6-phosphate dehydrogenase (G6PD) deficiency confers a relative
degree of protection against the malaria parasite and therefore
variations in G6PD are found to a greater extent in populations
whose ancestry derives from tropical regions such as Sub-Saharan
Africa and Southern Asia (7). Finally, a genetic variation may
arise naturally within a population, and a variant allele may
subsequently persist in that population as its effect is generally
neutral on normal survival and reproduction (8).
Domestication and man’s subsequent use of animals for
specific purposes has led to selective breeding based on
phenotypic characteristics such as production traits in farmed
species, size, speed, and/or endurance in beasts of burden, and
behavior and aesthetics in companion animals, with the resulting
creation of subpopulations within the different domestic species
such that modern breeds may bear little resemblance with
the ancient ancestor. This divergence is possibly the most
extreme in the domestic dog, Canis familiaris (9). Phylogenetic
analysis of the whole canine genome indicates that the modern
domestic dog is descended from the Eurasian gray wolf (Canis
lupus lupus), with the primary divergence occurring more than
fifteen thousand years ago. This genetic drift is considered to
be as a result of two “bottleneck” events, believed to have
occurred during domestication (10). More recently, breed-
specific bottlenecks have occurred, where canine breeds were
created from a small population of “founder” individuals with the
preferred phenotype, followed by inbreeding within that limited
population (10). This selection for different extreme phenotypes
within canine breeds by far exceeds artificial selection pressures
within other domestic animals, and currently, the UK Kennel
Club lists 221 canine breeds (11). This selection pressure has
the potential to lead to a higher proportion of genetic variants
within specific dog breeds, which might not occur in semi-feral
or “village” dog populations (12).
As a comparison, the domestic cat remains largely
phenotypically similar to its ancestor, Felis silvestris, as this
species has not undergone the extreme selection pressures of
other domesticated species (13). The Cat Fanciers’ Association
currently lists 42 cat breeds (14), of which 16 are “natural breeds”
and are thought to be from historical populations arising in
specific geographical locations, while the remaining breeds
were developed through relatively recent deliberate selection, or
“discovered” in feral or domestic populations over the past 50
years, and are usually defined as simple, single-gene variants,
such as genes for coat color and/or texture (13).
EVOLUTION OF PGX IN HUMAN AND
VETERINARY MEDICINE
Pythagoras is commonly credited with having first reported
that the adverse effect of fava beans (Vica fava), now known
to be acute haemolytic anemia, was associated with only some
individuals. In the modern scientific era, Sir Archibald Edward
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Garrod is considered to be the first scientist to recognize inherited
aspects of the metabolism of substances, with his description
of alkaptonuria, a rare inherited condition resulting in black-
colored urine due to an inability to metabolize ingested tyrosine
and phenylalanine, discussed in his 1923 book “Inborn Errors of
Metabolism” (15).
In the same decade, the 1920s, the anti-malarial drug 8-
aminoquinoline (pamaquine) was reported to induce acute
haemolytic anemia, primarily in African-Americans. The drug
primaquine was found to have the same adverse effect, and again
it was noted that African-Americans had a greater susceptibility
in comparison to persons of European descent (16). This ADR
and also the effect of fava beans were subsequently found to be
due to glucose-6-phosphate dehydrogenase (G6PD) deficiency,
which altered erythrocyte metabolism (17). In 1957, in a seminal
edition of the Journal of the American Medical Association,
Motulsky theorized that these adverse reactions were as a result of
genetic traits (18). Shortly afterwards in 1957 at an international
conference on modern problems in human genetics, Vogel
for the first time coined the term “Pharmakogenetik” (19)
establishing PGx as a distinct discipline.
Motulsky and collaborators went on to characterize the
human genetic variation in the pseudocholinesterase enzyme
associated with prolonged response to succinylcholine during
anesthetic induction (20).
Inter-individual variabilities in the rate of drug metabolism
were also being identified during the same timeframe as the
above ADRs. In the mid to late 50’s, isoniazid, an important drug
for treatment of tuberculosis, was found to have a variation in
the rate of metabolism in different ethnic groups- subjects were
found to be either “rapid” or “slow inactivators”. It was found,
for example, that the Japanese population contained a greater
proportion of “rapid inactivators” than the Caucasian population.
This was explained as a genetic variation in an acetylator enzyme
(21), and 40 years later was specifically identified as a genetic
variation in the gene encoding the metabolizing enzyme N-
acetyltransferase-2 (NAT-2) (22).
From the 1960s through to the 1980s, a range of studies
investigated inter-population and inter-individual variations in
drug metabolism. Studies on the wide variability in metabolism
of the antihypotensive agent debrisoquine led eventually to
the identification, cloning, and characterization of the first
known polymorphic drug-metabolizing enzyme -cytochrome
P450 enzyme (CYP)2D6 (23). By the end of the 1980s, more than
100 examples of pharmacogenetic responses had been identified
in the human, including exaggerated drug responses, lack of
expected drug efficacy, or novel drug effects (24).
As these human investigations proceeded, the variability in
metabolism was also being investigated in experimental animals,
primarily laboratory rodents. For example, dark agouti (DA)
rats were found to be “slow metabolisers” of debrisoquine in
comparison to either Fischer or Lewis strains (25) and therefore
the DA stain was used subsequently as a model of the CYP2D6
poor metaboliser phenotype (26).
Domestic animal species also served as experimental models
for heritable human disease. The animal model for the heritable
condition malignant hyperthermia (MH), a hypermetabolic
adverse reaction to succinylcholine and volatile anesthetics (27),
was first identified in 3 Landrace x cross pig littermates (28)
although the breed was not identified in the initial paper.
Subsequently, the Pietrain breed of pigs was found to have a high
likelihood of MH susceptibility. It was noted that pigs susceptible
to MH also have an increased likelihood of developing porcine
stress syndrome (PSS), which affects meat quality and appearance
(29) pointing to an issue relating to an excitable cell protein. The
genes responsible for MH in pigs was subsequently identified as
due to a ryanodine receptor 1 (RYR-1) mutation and RYR-1 gene
polymorphisms have since been identified in a range of pig breeds
(30). Following immediately on from this work in pigs, variation
in the homolog gene, human RYR-1, was identified as a genetic
biomarker for human MH (31).
Breed or population associated differences in drug responses
in companion animals did not receive major attention until
the emergence of the macrocyclic lactone ivermectin onto the
market in 1981, originally only licensed for use in farmed
species for external and internal parasites. Its effectiveness
led to off-label use of the large animal formulation in dogs.
By 1983, “ivermectin toxicity” was being reported in dogs,
particularly Collie and herding breeds (32) so that by the time
an ivermectin product was authorized for use in dogs in 1987
as a heartworm preventative, specific testing had been carried
out to ensure that the dosage chosen was safe in what were
termed “sensitive” breeds, specifically Collies (33). The role
of P-glycoprotein as a blood-brain barrier “gatekeeper” was
discovered as an “incidental finding” in experimental laboratory
animals. When ATP binding cassette subfamily B member 1a
(ABCB-1a, then named MDR-1a) knockout mice were treated
with ivermectin for mite infestation, nearly all of the group died
from neurotoxicity (34). Ivermectin toxicity in dogs was then
subsequently identified as a deletion mutation of the ABCB-1
gene encoding P-glycoprotein (35).
The scientific endeavor which revolutionized all aspects of
genetics and accelerated the rate of PGx discovery has been the
Human Genome Project, with the first full genome sequenced in
2001 (36). The dog and cat draft genomes were published in 2005
(37) and 2007 (38) respectively. Domestic cattle (Bos taurus) (39)
and horse (40) genome sequences were published in 2009.
The publication of these sequences has been accompanied by
an improved array of technologies to interrogate the generated
data and has contributed to the development of the discipline of
PGx. Whereas historically the study of genetic responses both
in human and veterinary medicine followed a “phenotype-to-
genotype” approach, these tools shift the dynamic of exploration
such that identified genomic variability may be scrutinized to
identify phenotypic variability (41).
PGX AND PHARMACOGENES
The tools available to the modern clinical scientist allow genetic
loci of interest to be targeted for genomic investigation. These loci
are often called “genomic biomarkers” andmay be used to predict
the likelihood that a person or animal may develop a disease
condition, and therefore predict medical “risk” (42). By the same
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token, specific loci have been identified to be associated with drug
responses, and have been named “pharmacogenes,” although it
is now known that many drug effects are under the influence of
multiple genes within the same patient.
A significant number of well-recognized “clinically actionable”
pharmacogenes have been identified in human medicine,
primarily encoding genes relating to pharmacokinetics (43). The
term “clinically actionable” in this context is described as using
knowledge of genetic variants, where there is clear evidence
of an effect, for guiding clinical decisions to improve health
outcomes (44).
PGx variances may be classified into groupings based
on the drug response “differences” which impact on drug
metabolism, efficacy, and risk of adverse effects. These group
profiles are (1) “pharmacokinetic,” reflecting genes that influence
absorption, distribution, metabolism, and elimination (ADME);
(2) “pharmacodynamic”- genes that encode the intended target
of the drug; (3) “pathway”- genes that encode proteins in the
downstream pathway (i.e., metabolic or cellular) of the drug; and
(4) “off-target”- genes that encode proteins that are not in the
intended pathway (2); see Table 1.
Genes Involved in Pharmacokinetic
Variation
Drug metabolism is characterized by two phases: (1) Phase I
metabolism primarily carried out by Cytochome P 450 (CYP)
hepatic microsomal enzymes and (2) Phase II metabolism which
normally involves conjugation with an ionized group (55).
A vast array of enzymes and pathways are involved in both
phases, and significant species differences exist. Considering the
complexity of the process of drug metabolism, it is not surprising
that the genes involved in drug metabolism are also complex.
Genes involved in pharmacokinetics are known to have multiple
polymorphic variations both in man (56) and in veterinary
species (48, 57). For example, the variability in response to
warfarin, a drug used extensively in human medicine as an
anticlotting agent, is influenced by both the gene encoding the
cytochrome P450 complex subunit 2C9 (CYP2C9) for which
there are 60 known human haplotypes, and also cytochrome
P450 complex subunit 4F2 (CYP4F2) a primary liver vitamin K
oxidase for which there are three haplotypes, and rs12777823,
a SNP in the CYP2C cluster which is associated with reduced
clearance in persons with African ancestry (45, 58). The case
of warfarin is further complicated by pharmacodynamic genetic
variation, specifically in the gene encoding the molecular target
for warfarin, vitamin K epoxide reductase subunit 1 (VKORC1)
(58) for which there are 13 known human haplotypes.
Although not as advanced as in human medicine, great strides
have been made in the study of pharmacokinetic variation
in veterinary species (59). Much of the current scientific
understanding of CYP metabolism has been elucidated in
humans and rodents, although in recent decades, exploration
has commenced in veterinary species (57). It is important to
note that interspecies differences in drug metabolism mean
that information derived from human gene-biomarker: probe
substance pairs do not automatically extrapolate to veterinary
species. The genetics of canine CYP, extensively reviewed in 2013
(60) shows specific similarities but also significant differences
from human CYP. There are species differences in gene
sequences, and therefore even where there are clearly identifiable
orthologs (genes derived from common and sometimes ancient
ancestral genes) the names may differ. As an example, CYP2D15
is the canine ortholog of human CYP2D6 (61). Human CYP2D6,
whose polymorphisms were first identified with debrisoquine,
is considered be involved in the metabolism of over 25% of
currently marketed drugs in humans, including antiarrhythmics,
adrenoceptor antagonists, and tricyclic antidepressants (62).
Canine CYP2D15 shares many, although not all therapeutic drug
substrates with human CYP2D6 (57) but has a greater relative
degree of expression in the normal canine the intestine and
liver than CYP2D6 in normal human intestine and liver, which
explains why drugs which are CYP2D16 substrates have lower
oral bioavailability in dogs than in humans (60). Notwithstanding
the importance of canine CYP2D15, to date no polymorphisms
have been identified which have been definitively proven to affect
canine drug metabolism (59).
This is not necessarily true of the horse, however, as
there is initial evidence that the equine ortholog for human
CYP2D6, the equine CYP2D50 gene, is polymorphic, and
effects on drug metabolism have been identified (48). This
study analyzed blood samples from only 150 horses, primarily
Thoroughbreds, and identified 126 exonic SNPs, of which
31 appeared in more than one horse. A subset of the
genotyped horses (23 Thoroughbreds, 1 Standardbred) were
administered the known human CYP2D6 substrate tramadol
by nasogastric tube, and subsequent plasma levels of tramadol
were measured, using jugular samples taken over the following
96 hours. Although the number of animals used was very
small, the resulting pharmacokinetic data is suggestive of
specific CYP2D50 SNPs being associated with slower drug
metabolism in horses, although further work is needed to
confirm this.
One example where canine CYP polymorphisms have been
identified is Canine CYP2B11, found primarily in Labrador
retrievers, Collies, Uraguayan Cimarrons, Silken Windhound,
Scottish Deerhounds, Greyhounds, and Welsh Corgis (59).
Canine CYP2B11 is the canine ortholog of the human clinically
actionable highly polymorphic pharmacogene CYP2B6, and
is considered to act on a number of important substrates
including propofol in both species (60). Although some of these
breed-associated polymorphisms have not yet been associated
with drug metabolism differences, the variant CYP2B11-
H3, a single SNP in 3′ untranslated region of mRNA
(59), may contribute to the previously identified reduction
in metabolism of propofol in greyhound in comparison
with mixed-breed canine hepatic microsomal preparations
(63). Other known substrates of CYP2B11 include a range
of drugs used frequently in veterinary practice, including
atipamezole, diclofenac, ketamine, medetomidine, midazolam,
and temazepam (60), and further evaluation of Canine CYP2B11
polymorphisms combined with hepatic microsomal studies
may inform the therapeutic use of these drugs in the
veterinary clinic.
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TABLE 1 | PGx variants determining drug responses.
Class Description Example genes or
gene products
Primary effect Example gene
biomarker and
drug pair- human
Example gene
biomarker and drug
pair- veterinary spp.
Potential clinical
approach
Pharmacokinetic Genes relating to
ADME
Cytochrome P 450
(CYP) enzymes, drug
transporters
Alter concentration of
the active drug at the
intended or at an
unintended site of
drug action
CYP2C9 and warfarin
(45)
CYP2D6 and codeine
(46)
CYP2B6 and
propofol (47)
Equine CYP2D50 and
tramadol (48)
Canine ABCB-1 and
ivermectin (35)
Change drug dose;
choose alternate
drug with different
ADME
Pharmacodynamic Genes that
encode the
intended drug
target
Cell surface receptors
and intracellular
enzymes
Alter the levels of the
drug target or alter
the ability of a drug to
bind to drug target
VKORC1 and
warfarin (45)
Canine OXTR and
oxytocin (49)
Canine PDE5A and
sildendafil (50)
Change drug dose;
choose alternate
drug with different
target
Pathway Genes that
encode proteins in
the downstream
pathway of drug
Signaling molecules,
cellular pathways,
transcription factors
Alter the activity of
the pathway targeted
by drug therapy
LDLR and statins (51) – Change drug dose;
choose alternate
drug with different
drug pathway
Off-target Genes that
encode proteins
that are not in the
downstream
pathway of drug
Immune recognition
proteins
Generate an immune
or other response to
drug or metabolite
HLA-B and abacavir
(52)
MHC genes and
idiosyncratic
responses?
Porcine (30), Canine
(53) & Equine (54)
RYR1 and
halothane/sevoflurane
Change drug dose;
choose alternate
drug with different
chemical structure
Adapted from Voora (2).
Pharmacokinetic difference may also involve drug
transporters, such as efflux transporters, which influence
the distribution, effects, and elimination of drugs. The family
of genes which encode for efflux transporters of the ATP-
binding cassette (ABC) are of ancient phylogenic origin, are
found in prokaryotes and eukaryotes, and where present and
functioning, are responsible for mediating a range of therapeutic
outcomes- from antimicrobial resistance in bacteria to failure
of chemotherapy in humans (64). Efflux transporters serve a
vital function to translocate substrates across cell membranes
and lower intracellular concentrations. In mammals, efflux
transporters are highly expressed in many organs such as the
intestine, brain, liver, kidney, adrenals, placenta, and lungs,
where their presence typically affects drug bioavailability,
distribution and elimination (65).
In human medicine, ATP-binding cassette B-1 (ABCB-1),
formerly known as the multi-drug resistance gene-1 (MDR-1), is
a listed as a “very important” pharmacogene, a concept explained
in section Translating PGx to the clinic, and is one of forty-nine
putative gene members in the superfamily of ABC transporters
that encode human cellular efflux pump P-glycoprotein (65). P-
glycoprotein is expressed across a broad range of tissues and
was first identified as a result of increased expression of this cell
surface protein in cancer cell lines which were resistant to certain
chemotherapeutics (66).
Substrates for P-glycoprotein in man and animals include a
functionally diverse range of therapeutic compounds (65), and
include anticancer agents such as doxorubicin and vincristine;
steroid hormones such as hydrocortisone and dexamethasone;
anti-histamines such as fexofenadine and cimetidine; opiates and
derivatives such as morphine and loperamide; and cardiac drugs
such as digoxin and quinidine (67, 68). Although functionally
variant alleles have been identified in different populations of
humans (69), as yet the drug substrate: gene pairs are not
listed as “clinically actionable” by the US Food and Drug
Administration (70).
The gene encoding P-glycoprotein in dogs and cats is also
named ABCB-1, and in these species clinically relevant ABCB-
1 polymorphisms have been identified. In dogs, as mentioned
previously, the veterinary importance of ABCB-1 came to
light when the anti-parasitic drug and P-glycoprotein substrate
ivermectin was introduced to the market (35). One ABCB-1
mutation in dogs consists of a 4 base-pair deletion at the 5′ end,
with the effect that p-glycoprotein synthesis is incomplete (35).
Loss of p-glycoprotein function is most commonly associated
with neurotoxicity and fatal toxicosis, as drugs which are
normally prevented from entry into the brain by the blood-brain
barrier may now enter and have a direct effect on brain neurons,
as occurred with ivermectin to disastrous effect. One case report
describes a Collie with ABCB-1 mutation which displayed severe
neurologic signs, including disorientation, ataxia, rear limb
weakness, when treated with oral loperamide at therapeutically
appropriate dose levels (71). Experiments in dogs using the
sedative drug and P-glycoprotein substrate acepromazine found
that those dogs which were homozygous for the mutation
showed increased sedative effects to IV acepromazine while dogs
which were heterozygous for the mutation did not differ from
genetically normal dogs (72).
As P-glycoprotein is normally expressed in liver and kidney,
a lack of functioning p-glycoprotein can result in reduction of
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clearance of substrates. This is particularly relevant in canine
cancer therapeutics, where there is a narrow therapeutic index,
and reported case studies include dogs with ABCB-1 mutations
undergoing chemotherapy for lymphoma which experienced
more severe adverse effects than expected to P-glycoprotein
substrates vincristine and doxorubicin (73, 74). A subsequent
prospective study found that dogs that are heterozygous or
homozygous for ABCB-1 mutation are more likely to experience
neutropenia and thrombocytopenia than normal/wild type
dogs (75).
It is proposed that the ABCB-1 mutation found in herding
breeds arose in the early 1800s in Great Britain, in a common
“founding” ancestor before the creation of breed registries (76).
A recent evaluation of the prevalence of the mutation in the
UK found that allelic frequency was highest for Rough (71 per
cent) and Smooth (73 per cent) Collies, followed by Australian
Shepherd dogs (46 per cent), Shetland sheepdogs (36 per cent),
old English sheepdogs (11 per cent), and Border Collies (2 per
cent), although the allele was not found in Bearded Collies. The
study had concentrated primarily on herding breeds, and as only
low numbers of other breeds had been used the presence of the
allele in further breeds cannot be ruled out (77).
One relatively small US study of 100 banked feline samples
found 5 animals with a two base pair deletion in the ADCB-
1 gene, with one animal homozygous for this variant allele.
This mutation results in a frameshift generating a series of stop
codons immediately downstream from the deletion, resulting in
a non-functional P-glycoprotein (78). However, breed data was
not provided, and also as the samples derived from a limited
population of cats in the catchment area of Washington State
University Veterinary hospital; it is possible that this mutation
is not yet widespread in the international feline population.
Genes Involved in Pharmacodynamic
Variation
Pharmacodynamics reflect a drug’s ability to influence drug
targets, normally a drug receptor or enzyme, and may involve
both intended and unintended effects (2). Pharmacodynamic
variation examples include genetic variation in expression levels
in the target, such as with the human molecular target for
warfarin, VKORC1 mentioned previously (58).
One example of a receptor polymorphism which has a strong
effect on canine behavior is the gene encoding the oxytocin
receptor OXTR. Oxytocin is considered to play an important
role in human-animal interactions (79). A Swedish study,
using Golden Retriever dogs and Eurasian wolves, identified
polymorphisms located in the 3
′
untranslated region immediately
after the last exon of the dog OXTR-gene in both groups. One
homozygous OXTR genotype (“AA”) was associated in dogs
with increased human-directed social behavior in response to
intranasal oxytocin, while the opposite was true of a second
homozygous genotype (“GG”) (49). It is not clear as yet how this
difference translates to therapeutic clinical practice.
One further polymorphism that may potentially be of
importance in canine therapy relates to canine phosphodiesterase
5A (PDE-5A). The PDE-5 inhibitor sildenafil (Viagra)
induces vasodilation through by increasing pulmonary
vascular concentrations of cyclic guanosine monophosphate
(cGMP), and is one of the recommended treatments for
pulmonary hypertension (PH) in dogs (80). However, an exonic
polymorphism has been identified in a range of canine breeds
that alters the amino acid sequence of PDE-5 and is associated
with significantly lower cGMP concentrations in healthy dogs
that are homozygous for the polymorphism. This may explain
the variability in response to sildendafil in dogs with PH (50).
Genes Involved in “Pathway” Variation
In human medicine, statins are used primarily to reduce blood
cholesterol and thereby reduce the risk of arteriosclerosis and
adverse cardiac events. A lack of response may be attributed
to a “pathway” pharmacogenetic difference. Statins target 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase,
the enzyme involved in the biosynthetic pathway for cholesterol,
leading to a decreased concentration of cholesterol in the cell.
This lowering of intracellular cholesterol normally stimulates the
synthesis of the LDL receptors (81) but with homozygous familial
hypercholesterolemia, a condition caused by mutations in the
low-density lipoprotein receptor (LDLR), patients may respond
poorly or not at all to statin therapy (82).
As of yet, the authors can find no clear example of a specific
“pathway” pharmacogenetic difference in veterinary species.
Genes Involved in “Off-Target” Variation
The exemplar for an “off-target” effect in human medicine is
the case of the major histocompatibility class I human leukocyte
antigen-B (HLA-B) and the antiviral drug abacavir. Candidates
for treatment with abacavir must be tested for the allele HLA-
B∗5701, as this allele is associated with idiosyncratic drug
reactions to abacavir which presents in the first 6 weeks of
treatment, includes skin rash and fever, and can be severe and
life-threatening (83). Abacavir binds the peptide-binding groove
of HLA-B∗57:01, allowing the presentation of peptides that
normally cannot be bound by the HLA-B complex (84).
In veterinary medicine, there are a number of well-known
idiosyncratic responses to drugs, many of which present
as immune-mediated reactions (85). Both feline (86) and
canine (87) histocompatibility complex genes are known to be
polymorphic: it is likely that future research will identify the
alleles associated with immune-mediated drug reactions.
Malignant hyperthermia (HM) is a rare inherited
hypermetabolic condition caused by an uncontrolled elevation
of skeletal muscle cytoplasmic calcium ions, leading to strong
muscle contractures, metabolic and respiratory acidosis, and
dangerously elevated body temperature (31). As described
previously, the study of MH was accelerated by recognition of
the porcine presentation of MH, which allowed the development
of the pig experimental animal model. It is now understood that
depolarising muscle relaxants such as succinylcholine trigger
MH, and also inhalant anesthetics other than nitrous oxide (88).
Volatile anesthetics induce their effects through acting on a
range of targets in excitable tissue, although the intended targets
are voltage-gated channels, excitatory receptors and inhibitory
receptors in the brain and spinal cord. Although the mechanism
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is not fully understood, all manifestations of MH are considered
associated with some form of autosomal dominant variation in
the ryanodine receptor RYR-1. MH has been documented in
humans, pigs, horses, dogs, and cats (89). Porcine MH presents
clinically in a very similar fashion to human MH but develops
much more rapidly. The mutation identified in pigs consists of a
cysteine for arginine transposition in the RYR-1 gene (30). MH
has also been identified in horses, and presents very similarly
to MH in humans, evolving over 3–4 h of anesthesia (89). The
mutation found in horses to date is a missense base substitution
in the RYR-1 gene which results in an amino acid substitution
(54). In dogs, the RYR-1 mutation has been identified as a T to
C substitution that changes an amino acid codon from valine
to alanine (V547A) in a highly conserved region of the canine
RYR-1 gene (53). Although specific breeds have been proposed
to present more frequently with MH, all dogs are considered
potentially susceptible (89).
TRANSLATING PGX TO THE CLINIC
In human medicine, the challenges and obstacles which act as
barriers to implementation of PGx have been discussed for more
than 10 years, and are still ongoing (3, 90–92). The steps are
outlined in Figure 1.
The outputs from basic and clinical research have resulted in
the identification of a significant number of “clinically actionable”
pharmacogenes. One methodology which has added significantly
to PGx knowledge is genome-wide association studies (GWAS)
(93). This technique used microarrays of millions of SNPs, large
genome databases, and statistical computing to determine the
probability that specific variants are associated with a disease, or
with an ADR. PGx examples found by GWAS include variants
in CYP2CI9 and resulting guidance of the dose of clopidogrel,
and also variants in interleukin 2B and guidance on use of
interferon-α (94).
In the European Union, medicines may be authorized
by either an individual member state or via a centralized
authorization procedure administered by the European
Medicines Agency. More than 15% of the 517 human medicines
that the European Medicines Agency has evaluated since central
authorization commenced in 1995 include PGx information in
the advisory documentation (95). In the USA, where there is a
single authorization authority for medicines, the Food and Drug
Administration (FDA) has added PGx information to over 200
authorized drug products used in human medicine, in some
cases including recommendations for specific genetic tests to
pre-screen patients before specific drugs are used (70). As an
example, the FDA’s “boxed” warning on the package insert of the
anticonvulsant drug carbamazepine, it recommends that prior to
prescribing physicians should screen patients of Asian ancestry
for the MHC-I human leukocyte antigen-B HLA-B∗1502
allele, due to the increased risk of fatal dermatologic reactions,
including toxic epidermal necrolysis (TEN) and Stevens-Johnson
syndrome (SJS) (96).
Despite this information, from USA survey results published
in 2012 (97) and a further European survey in 2017 (98), human
FIGURE 1 | Steps and challenges in bringing PGx to the veterinary clinic,
based on Figure 1 from Swen et al. (3).
physicians have an awareness of PGx, but on the whole, they
do not yet feel confident in use of PGx data. Moreover, the
addition of such data by regulatory bodies has not been without
consequences in human medicine. When screening for HLA-
B∗1502 was introduced as a routine service by the Hong Kong
medical services, new prescriptions for carbamazepine declined
dramatically overall despite only 17% of the tested population
proving to be HLAB∗15:02 positive, as clinicians chose drugs
that did not require genetic testing. Instead, prescriptions for
other drugs increased, one of which was phenytoin, a drug
structurally similar to carbamazepine and which is also associated
with TEN/SJS but which at the time did not have an FDAwarning
relating to HLA-B∗1502 (99).
In human medicine, further challenges to the clinical use
of PGx data include lack of evidence for improved patient
care through PGx testing and perceived lack of guidelines
for translating genetic test results into clinical decision-
making (3). To begin to address this, a significant tool for
dissemination of PGx information to physicians has been
the creation of the Pharmacogenomics Knowledgebase (100).
This is an online, freely available resource that collects and
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disseminates evidence-based human PGx information and
currently lists and provides detailed information, including links
to supporting literature on 65 “Very Important Pharmacogenes”
(VIPs) in humans, the latter having been chosen following an
extensive review of FDA pharmacogenetic information from and
Clinical Pharmacogenetic Implementation Consortium (CPIC)
nominations (100).
The sheer volume of data now presented to the clinician
means that electronic medical recording systems (EMR)
combined with computerized clinical guidance must form a key
element in the realization of personalized medicine (101) and
therefore the most exciting development in human PGx is the
developing linkages between patient EMR and PGx data. In
the US, EMR systems have been in widespread use for over
a decade (102). In Europe, where EMR systems are in place
at a national level in a number of EU states, combined with
social welfare-based healthcare, there is considerable potential
to link patient information with prescribing practice. In 2015,
the Council of the European Union adopted conclusions on
personalized medicine, and invited member states to support
efforts to bring personalized medicine to fruition (103).
The Ubiquitous-Pharmacogenomics (U-PGx) Consortium
is an example of a recent ongoing EU-funded collaborative
effort to bring PGx to clinical decision-making across Europe.
This project arose from work initially carried out by the
Dutch Pharmacogenomics Working Group (DPWG) (5). The
realization of the U-PGx project relies on a complex IT
support system for integration of PGx test results with EMR
systems and clinical decision support systems. Such EMR
systems are currently operational in several, but not all EU
countries, and for this project, seven implementation countries
will be Austria, Great Britain, Greece, Italy, Netherland,
and Spain. Once IT resources, guidelines, and training are
in place, the second phase involves pre-emptive genotyping
of >8,000 patients using a panel of 50 variants in 13
pharmacogenes into clinical practice, as part of a large
prospective, international, block-randomized, controlled study
named PREPARE (PREemptive Pharmacogenomic testing for
preventing Adverse drug REactions) (5). The third phase will
focus on expanding on and integrating knowledge of the
influence of genetic variation on drug response, while the fourth
phase will focus on ethical and legal issues associated with PGx
implementation (104).
The later processes will also include a cost-benefit analysis
of the utility of large-scale pharmacogenomic testing. Cost-
effectiveness of PGx is an ongoing concern in human medicine
(3, 91), although a recent meta-analysis has concluded that in a
future where personal genomic information is available as part of
normal EMR, the majority of economic evaluations would find
PGx to be cost-effective (105). In countries where healthcare is
primarily funded through taxes, the final decision-making on
the utility of PGx testing will be taken by governmental health
departments, and therefore human medical economics do not
translate directly to veterinary medical economics. In veterinary
medicine, costs associated with DNA testing are borne primarily
by the animal owner, and data are likely to be held within
privately-owned corporate databases. In comparison with human
medicine, progress in PGx-driven prescribing in veterinary
medicine has been slow to date, although, from a recent, critical
and bioethically focused opinion piece published in Nature,
pet genetic testing has become a “booming industry” and at
least one US corporate veterinary hospital chain recommends
genetic testing in order to “enable proactive, individualized
healthcare” (106).
Current progress in the steps toward the clinic in veterinary
medicine appears to be at an early “clinical research” stage,
although international collaborative efforts are becoming visible
in the domain of animal genetic testing (59). Currently, there
are several information sources regarding genetic diseases in
veterinary species, which include PGx variation. The most
extensive is the website OnlineMendelian Inheritance in Animals
(OMIA), an academia-led and evidence-based site (107). This
site provides a catalog of inherited traits in a broad range of
animal species and includes pharmacogenes, however most of
the pharmacogene findings reported are based on small-group
studies. Genome-wide association studies are being used to
identify genetic loci associated with disease in veterinary species,
but as yet these have been limited in comparison with human
studies, and also these have not focussed on PGx differences
(106). This means very little statistically robust PGx data is
currently available to veterinary clinicians, and commercially
available PGx tests appear to be currently limited to two tests
in dogs: one form of the ABCB-1 (listed as MDR-1) mutation,
and one form of malignant hyperthermia (RYR-1) mutation.
At the current state of veterinary genomics databasing, any
claim by veterinary businesses that they can currently provide
personalized medicine does not stand up to close scrutiny,
nor can the majority of tests available in veterinary medicine
truly guide therapy for improved health. The one group of
animals for which pharmacogenetic testing should be considered
“standard of care” are those canine breeds with a high risk of
ABCB-1 mutation, particularly when treatment with vincristine,
vinblastine, doxorubicin, loperamide, or a macrocyclic lactone is
proposed (108, 109).
Pet genetic testing is unregulated, unlike human genetic
testing in many jurisdictions. For quality assurance, the World
Health Organization advocates regulatory oversight of genetic
testing, and provides a benchmark regarding what such quality
assurance should look like, from the point where the clinician
decides whether a test is warranted, to the validity of the
test, the accreditation of the laboratory and the interpretation
of the results combined with counseling of the client/patient
(110). Although this is a broader discussion than PGx, as pet
genetic databases expand, there will need to be ongoing discourse
regarding the ethics in and around the data generated: where and
how long the data is to be stored, who is to be responsible for
data sharing, how will data on individual animals affect insurance
and the responsibility and/or potential liability of dog breeders
toward owners (106).
Despite all of these concerns, there remains genuine scope for
advances in PGx as genetic databases expand, with real scope for
collaborative efforts between the private genetic companies and
independent academic veterinary researchers to solve therapeutic
problems and differences in responses. Owner investment in
Frontiers in Veterinary Science | www.frontiersin.org 8 February 2019 | Volume 6 | Article 22
Campion and Dowell RRH: Translating PGx to the Clinic
genetic tests, with permission, may serve as a form of “crowd-
funding” for genome-wide association studies, and in addition,
the potential for the databases to provide insight into disease
processes may permit funding under the “one-health” banner.
CONCLUSION
Human medicine stands at the brink of realization of
personalized medicine, with plans in place at European Health
policy level to deliver real outcomes by 2025. As personalized
human medicine evolves, the pet owners will expect veterinary
medicine to follow suit, but the risk is that without regulation,
validation and international collaboration, personalized pet PGx
data will be limited and primarily within the ownership of private
genetic industry. Despite this risk, there are real opportunities to
improve animal health, if owners, clinicians, genetic companies,
and researchers work together with the goal that both animals
and humans may benefit from this genomic revolution.
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